Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1270

Related Citations for PubMed (Select 17504517)

1.

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.

Breast Cancer Res. 2007;9(3):R30.

2.

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.

Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J.

Acta Oncol. 2000;39(3):327-33.

PMID:
10987229
3.

p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U.

J Natl Cancer Inst. 1993 Jun 16;85(12):965-70.

PMID:
8496982
4.

Prediction of breast cancer prognosis by gene expression profile of TP53 status.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C.

Cancer Sci. 2008 Feb;99(2):324-32. doi: 10.1111/j.1349-7006.2007.00691.x.

PMID:
18271932
5.
6.

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.

7.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL.

Clin Cancer Res. 2006 Feb 15;12(4):1157-67.

8.

A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.

Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J.

Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.

PMID:
18465328
9.

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA.

Br J Cancer. 1998 Apr;77(7):1130-6.

10.

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.

Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL.

Breast Cancer Res Treat. 2007 Nov;105(3):255-65. Epub 2007 Jan 13.

PMID:
17221157
11.

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.

Mod Pathol. 2002 Aug;15(8):853-61.

12.

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.

Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR.

Ann Oncol. 2000 Mar;11(3):307-13.

13.

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.

Berns EM, Klijn JG, Smid M, van Staveren IL, Look MP, van Putten WL, Foekens JA.

Genes Chromosomes Cancer. 1996 Jul;16(3):170-9.

PMID:
8814449
14.

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL.

J Natl Cancer Inst. 1993 Feb 3;85(3):200-6.

PMID:
8423624
15.

The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J.

J Natl Cancer Inst. 1996 Feb 21;88(3-4):173-82.

17.

Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.

Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C.

Cancer Res. 2000 Feb 15;60(4):1077-83.

18.

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.

Clin Cancer Res. 2003 Mar;9(3):923-30.

19.

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J.

Ann Oncol. 2005 May;16(5):743-8. Epub 2005 Mar 31.

20.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk